Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 1, 2005, Pages 48-55

  Thistlethwaite, Fiona ^a   Mansoor, Wasat ^a   Gilham, David E ^a   Hawkins, Robert E ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adoptive immunotherapy; Chimeric immune receptor; Co stimulation; Gene transfer; Interleukin 2

Indexed keywords

ADENOSINE DEAMINASE; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIBODY; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIBODY ENGINEERING; ANTIGEN PRESENTING CELL; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVATION; CELL BASED GENE THERAPY; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CHIMERA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; EX VIVO STUDY; GENETIC ENGINEERING; HAZARD ASSESSMENT; HUMAN; IMMUNOSTIMULATION; IMMUNOTOXICITY; LYMPHOCYTOPENIA; MALIGNANT TRANSFORMATION; MELANOMA; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION;

CELL PROLIFERATION; HUMANS; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 14244265418     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410 6832):1107-1111.
2. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10 9):909-915.
3. Mapara MY, Sykes M: Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol (2004) 22(6):1136-1151.
4. Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA (1989) 86(24):10024-10028.
5. Pule M, Bollard CM, Heslop HE: Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther (2002) 4(5):467-475.
6. Hombach A, Hauser C, Abken H: The recombinant T cell receptor strategy: Insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther (2002) 2 2):211-226.
7. Hawkins RE, Whittington HA, Watkins SJ, Gilham DE: Antibodies: From genes to targeted cancer gene therapy. Gene Ther (1998) 5(12):1581-1583.
8. Moritz D, Groner B: A spacer region between the single chain antibody- and the CD3 ζ-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther (1995) 2(8):539-546.
9. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, Hawkins RE: Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3ζ-based chimeric immune receptors. J Immunother (2002) 25(2):139-151.
10. Sadelain M, Riviere I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 3 1):35-45.
11. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W, Pohl C, Abken H: A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther (1999) 6(2):300-304.
12. Xavier R, Brennan T, Li Q, McCormack C, Seed B: Membrane compartmentation is required for efficient T cell activation. Immunity (1998) 8(6):723-732.
13. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, Darcy PK: Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcERI-γ. J Immunol (2001) 166(1 ):182-187.
14. Heuser C, Hombach A, Losch C, Manista K, Abken H: T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther (2003) 10(17):1408-1419.
15. Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL: Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther (2002) 9(7):613-623.
16. Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, Clark TN, Zhang F, Slovak ML, Wu AM, Forman SJ, Raubitschek A: Human T lymphocyte genetic modification with naked DNA. Mol Ther (2000) 1(1):49-55.
17. Frauwirth KA, Thompson CB: Activation and inhibition of lymphocytes by costimulation. J Clin Invest (2002) 109 3):295-299.
18. Brocker T, Karjalainen K: Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes J Exp Med (1995) 181(5):1653-1659.
19. Alvarez-Vallina L, Hawkins RE: Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol (1996) 26(10):2304-2309.
20. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M: Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med (1998) 188(4):619-626.
21. Finney HM, Lawson AD, Bebbington CR, Weir AN: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (1998) 161 6):2791-2797.
22. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H: T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res (2001) 61 5):1976-1982.
23. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol (2002) 20 1):70-75.
24. Eshhar Z, Waks T, Bendavid A, Schindler DG: Functional expression of chimeric receptor genes in human T cells. J Immunol Methods (2001) 248(1-2):67-76.
25. Haynes NM, Trapani A Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 100(9):3155-3163.
26. Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK: Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol (2004) 173(3):2143-2150.
27. Finney HM, Akbar AN, Lawson AD: Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol (2004) 172(1):104-113.
28. Imai C, Campana D: Genetic modification of T cells for cancer therapy. J Biol Regul Homeost Agents (2004) 18 1):62-71.
29. Geiger TL, Nguyen P, Leitenberg D, Flavell RA: Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood (2001) 98(8):2364-2371.
30. L promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther (2002) 9(8 ):527-535.
31. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA (2002) 99(25 ):16168-16173.
32. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
33. Hege KM, Broad DF, Roberts MR, Warren RE, Fisher GA, McArthur J: T cell gene therapy of colorectal cancer with autologous CC49-ζ gene-modified CD4 and CD8 T cells. Am Soc Clin Oncol (1998) 34: Abs 1649.
34. Sauce D, Rufer N, Mercier P, Bodinier M, Remy-Martin JP, Duperrier A, Ferrand C, Herve P, Romero P, Lang F, Tiberghien P, Robinet E: Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. Blood (2003) 102(4):1241-1248.
35. Ferrand C, Robinet E, Contassot E, Certoux JM, Lim A, Herve P, Tiberghien P: Retrovirus-mediated gene transfer in primary T lymphocytes: Influence of the transduction/selection process and of ex vivo expansion on the T cell receptor β chain hypervariable region repertoire. Hum Gene Ther (2000) 11(8 ):1151-1164.
36. Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE: T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer (2003) 88(7):1119-1127.
37. Kim JV, Latouche JB, Riviera I, Sadelain M: The ABCs of artificial antigen presentation. Nat Biotechnol (2004) 22 4):403-410.
38. Coito S, Sauce D, Duperrier A, Certoux JM, Bonyhadi M, Collette A, Kuehlcke K, Herve P, Tiberghien P, Robinet E, Ferrand C: Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells. Stem Cells Dev (2004) 13(1):71-81.
39. Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW: A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma Clin Cancer Res (2003) 9(10 Pt 1):3562-3570.
40. Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B et al: Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood (2003) 102(6):2004-2013.
41. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 3 2):133-146.
42. Emtage PC, Clarke D, Gonzalo-Daganzo R, Junghans RP: Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J Immunother (2003) 26 2):97-106.
43. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, Miyoshi H, Kawarada Y, Katoh H, Takeshima T, Nishimura T: Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res (2004) 64(4):1490-1495.
44. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Riviere I, Sadelain M: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interieukin-15. Nat Med (2003) 9(3):279-286.
45. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK: Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood (2002) 99(6):2009-2016.
46. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA et al: Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood (2000) 96 3):785-793.
47. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF et al Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 96(2):467-474.
48. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L et al: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 25(3):243-251.
49. Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA (2004) 101(Suppl 2):14639-14645.
50. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN: T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest (2002) 110(2):185-192.
51. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 9 2):606-612.
52. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol (1999) 163 10):5211-5218.
53. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T: Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med (2001) 194(11):1549-1559.
54. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med (2000) 343(11):750-758.
55. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ et al: Allogeneic lymphocytes induce tumour regression of advanced metastatic breast cancer. J Clin Oncol (2004) 22 19):3886-3892.
56. Sheen AJ, Irlam J, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE, Gilham DE: Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum (2003) 46(6):793-804.
57. Hammarstrom S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol (1999) 9(2):67-81.
58. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D et al A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer (2002) 87(6):600-607.
59. Alvarez-Vallina L, Agha-Mohammadi S, Hawkins RE, Russell SJ: Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J Immunol (1997) 159 12):5889-5895.
60. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 348(3):255-256.
61. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorrensen R et al: LMO2-associated clonal T cell proliferation in two patients after gone therapy for SCID-X1. Science (2003) 302(5644):415-419.
62. McCormack MP, Rabbitts TH: Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2004) 350(9):913-922.
63. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL: Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction N Engl J Med (1990) 323(9):570-578.
64. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P et al: T lymphocyte-directed gene therapy for ADA- SCID: Initial trial results after 4 years. Science (1995) 270(5235):475-480.
65. Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, Matsumoto S, Kotani H et al: Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood (1998) 91(1):30-36.
66. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W et al: Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: Long-term results of the first clinical gene therapy trial. Blood (2003) 101(7):2563-2569.
67. Fischer A, Hacein-Bey S, Cavazzana-Calvo M: Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol (2002) 2(8):615-621.
68. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y: Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions Biochem Biophys Res Commun (1987) 149(3 :960-968.